Merck, Sanofi Exploring Potential End To Joint Venture In Europe
Bloomberg reported after Monday's market close that Merck & Co., Inc. (NYSE: MRK) and Sanofi SA (ADR) (NYSE: SNY) may discontinue a 20-year long joint venture to sell vaccines in Europe.
The joint venture, named Sanofi Pasteur MSD, represents a 50/50 ownership stake between the two companies and recorded total sales of around $330 million in the first six months of last year. The companies jointly sale flu vaccines and shots against shingles and the cervical cancer vaccine Gardasil.
Bloomberg, citing "people familiar with the situation," reported that the companies may end their relationship due to declining sales Sanofi's plans to reorganize its operations. In fact, sales have grown in only one of the past seven quarters, the report added.
Shares of Merck were trading lower by 0.93 percent at $50.28 shortly after Tuesday's opening bell, while shares of Sanofi were lower by 1.83 percent at $40.88.
See more from Benzinga
EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
Merck Confirms FDA Approval Of Hep C Drug At A Cost Of ,600 Per Patient
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.